Organization | The Jewish General Hospital, Montreal QC, Canada

The Jewish General Hospital, Montreal QC, Canada Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Organization Overview

First Clinical Trial

2012

NCT01382745

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Dr. Jean-Francois Morin | Dr. Te Vuong | Gerald Batist | Jewish General Hospital (Montreal, Quebec, Canada) | The Jewish General Hospital, Montreal QC, Canada | The Jewish General Hospital, Montreal, QC Canada | Wilson Miller

Active Ingredients

Drugs in Phase 4 Trials (2)

rivaroxaban (xarelto) (1 trial)

tinzaparin (Innohep) (1 trial)

Drugs in Phase 2 Trials (8)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (2 trials)

durvalumab (imfinzi) (1 trial)

nimotuzumab (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

regorafenib (stivarga) (1 trial)

tremelimumab (Imjudo) (1 trial)

Drugs in Phase 1 Trials (4)

dexamethasone (1 trial)

gemcitabine (gemzar) (1 trial)

rituximab (rituxan) (1 trial)

venetoclax (venclexta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Melanoma (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 14